Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...

The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...

Data from the Phase II trial saw three of the seven patients dosed with CAN-2409 surviving for more than 35 months.

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

Candel (CADL) stock fell 20% Tuesday after the company reported final overall survival data from a Phase 2 study of its drug ...

The US Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application ...

The test has met coverage requirements for use with patients with non-small cell lung cancer with resectable or unresectable disease in the surveillance setting.

Neoadjuvant Opdivo with platinum-doublet chemo had a statistically significant and clinically meaningful improvement versus ...

Candel Therapeutics (CADL) announced final overall survival data from the completed randomized controlled phase 2 clinical trial of CAN-2409 ...

Shares of Candel Therapeutics , Inc. (NASDAQ: CADL) climbed 8% following the announcement of favorable final survival data from their phase 2 trial of CAN-2409, a treatment for pancreatic cancer. The ...

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with head and neck cancer.